<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375098</url>
  </required_header>
  <id_info>
    <org_study_id>200415015</org_study_id>
    <nct_id>NCT04375098</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection</brief_title>
  <official_title>Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Arturo Lopez Perez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no standard treatment for SARS-CoV-2 infection. Use of convalescent plasma
      has been studied in outbreaks of other respiratory infections, including SARS-CoV-1 ,
      MERS-CoV and Hantavirus infection. This study is an open-label randomized trial in which
      patients with high risk of COVID19-associated respiratory failure will be randomized to early
      treatment with convalescent plasma (≤ 7 days from symptoms start) or at early signs of
      respiratory failure or prolonged hospitalization. COVID-19 convalescent plasma will be
      collected from individuals according to the institutional protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Actual">August 17, 2020</completion_date>
  <primary_completion_date type="Actual">August 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization</measure>
    <time_frame>1 year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median duration of fever</measure>
    <time_frame>1 year</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of mechanical ventilation</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median length of ICU stay</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median length of admission</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality rate (percentage)</measure>
    <time_frame>1 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality (percentage)</measure>
    <time_frame>1 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate (percentage)</measure>
    <time_frame>1 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median length of viral clearance</measure>
    <time_frame>1 year follow up</time_frame>
    <description>days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <arm_group>
    <arm_group_label>Early COVID-19 convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for &gt;7 days after enrolment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 convalescent plasma</intervention_name>
    <description>COVID-19 convalescent plasma</description>
    <arm_group_label>COVID-19 convalescent plasma</arm_group_label>
    <arm_group_label>Early COVID-19 convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient older than 18 years

          -  CALL score ≥ 9 (progression risk score)

          -  PCR-confirmed COVID-19 infection with equal or less than 7 days of symptoms (or
             imaging consistent with COVID-19 pneumonia and confirmed COVID-19 contact)

          -  Any symptoms of COVID-19 infection

          -  Admission due to COVID-19 infection

          -  Signed informed consent

          -  ECOG before COVID-19 infection 0-2

        Exclusion Criteria:

          -  PaFi &lt;200 or mechanical ventilation indication

          -  Clinically relevant co-infection at admission

          -  Pregnancy or lactation

          -  IgA deficiency or IgA nephropathy

          -  Immunoglobulin or plasma administration in the last 60 days

          -  Contraindication to transfusion or previous allergy to blood-derived products

          -  Do-not-resuscitate status

          -  Patients receiving other investigational drug for COVID-19 in a clinical trial

          -  Any condition, that in opinion of the investigator may increase the risk associated
             with study participation or interfere with the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Elvira Balcells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ebalcells@uc.cl</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universidad Católica</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>September 12, 2020</last_update_submitted>
  <last_update_submitted_qc>September 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma</keyword>
  <keyword>COVID-19</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

